Amorphous Solid Dispersion for BRAF Inhibitor Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of biologically active compounds, such as BRAF inhibitors, face challenges in achieving efficacious and safe delivery due to limitations in bioavailability and stability, particularly for treating BRAF-mediated diseases like metastatic melanoma and thyroid cancers.
Innovation Solution
Development of solid dispersions comprising a substantially amorphous Compound I, molecularly dispersed within a polymer matrix like hydroxypropylmethyl cellulose acetate succinate (HPMCAS), combined with excipients and solubilizing agents, to enhance bioavailability and stability, and administered with CYP inhibitors to improve therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional formulations of BRAF inhibitors are used, then the compound can be administered, but bioavailability and stability are insufficient for effective treatment
Solution Approach 1:
The patent transforms the crystalline compound into an amorphous form, changing its physical state from ordered to disordered molecular arrangement. This parameter change dramatically improves solubility and bioavailability without requiring complex formulation systems, directly resolving the contradiction between reliability and complexity
Solution Approach 2:
The patent creates a solid dispersion by combining the amorphous compound with a polymer matrix (such as HPMCAS). This composite material approach enhances both stability and bioavailability through the synergistic interaction between the drug and polymer, achieving reliable delivery without excessive formulation complexity
2Stability of the object's composition
If crystalline form of Compound I is used, then the formulation is stable, but solubility and bioavailability are limited
Solution Approach 1:
The patent exploits the phase transition from crystalline to amorphous state. The amorphous form, while less stable in isolation, is stabilized within the polymer matrix, achieving both improved solubility and maintained stability. This phase transition approach directly addresses the contradiction between stability and solubility
Solution Approach 2:
The polymer matrix acts as an intermediary between the compound and the aqueous environment. It stabilizes the amorphous compound while simultaneously enhancing its solubility and bioavailability, resolving the contradiction between formulation stability and drug solubility
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solid dispersion formulation significantly improves the bioavailability and therapeutic effectiveness of Compound I, achieving higher exposure levels and target efficacious concentrations, thereby enhancing treatment outcomes for BRAF-mediated diseases.
Implementation Method 1
solid dispersions comprising a substantially amorphous Compound I, molecularly dispersed within a polymer matrix like hydroxypropylmethyl cellulose acetate succinate (HPMCAS)
Data Source
Figure 1
Figure 2
AI summary
Provided are solid dispersions of Compound I having the formula: Compound I, wherein Compound I is substantially amorphous, methods of manufacturing said solid dispersions, and methods of using said solid dispersions.